Cancer Immunotherapy-targeted Glypican-3 or Neoantigens

Overview

Journal Cancer Sci

Specialty Oncology

Date 2017 Dec 30

PMID 29285841

Citations 28

Authors

Yasuhiro Shimizu

Toshihiro Suzuki

Toshiaki Yoshikawa

Nobuhiro Tsuchiya

Yu Sawada

Itaru Endo

Tetsuya Nakatsura

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican-3 an HLA-24, HLA-A2 restriction peptide with extreme cancer specificity. In this paper, we summarize results from a number of related clinical trials showing that glypican-3 peptide vaccines induce specific CTLs in most patients (UMIN Clinical Trials Registry: UMIN000001395, UMIN000005093, UMIN000002614, UMN000003696, and UMIN000006357). We also describe the current state of personalized cancer immunotherapy based on neoantigens, and assess, based on our own research and experience, the potential of such therapy to elicit cancer regression. Finally, we discuss the future direction of cancer immunotherapy.

Citing Articles

Cancer vaccines: platforms and current progress.

Lei W, Zhou K, Lei Y, Li Q, Zhu H Mol Biomed. 2025; 6(1):3.

PMID: 39789208 PMC: 11717780. DOI: 10.1186/s43556-024-00241-8.

SPP1+ macrophages and FAP+ fibroblasts promote the progression of pMMR gastric cancer.

Su Z, He Y, You L, Chen J, Zhang G, Liu Z Sci Rep. 2024; 14(1):26221.

PMID: 39482333 PMC: 11528032. DOI: 10.1038/s41598-024-76298-w.

Administration of a glypican-3 peptide increases the infiltration and cytotoxicity of CD8 T cells against testicular yolk sac tumor, associated with enhancing the intratumoral cGAS/STING signaling.

Zhao J, Qin L, He G, Xie T, Hu G, Wang F Cancer Med. 2023; 12(23):21293-21307.

PMID: 37986544 PMC: 10726841. DOI: 10.1002/cam4.6605.

Innate immune response restarts adaptive immune response in tumors.

Li W, Zhang Q, Li Q, Liu S, Yuan G, Pan Y Front Immunol. 2023; 14:1260705.

PMID: 37781382 PMC: 10538570. DOI: 10.3389/fimmu.2023.1260705.

Comparison of the clinical efficacy of donafinil and lenvatinib in the treatment of intermediate and advanced hepatocellular carcinoma.

He Q, Guo M, Ya Y, Huang J, Liu A, Jing W Am J Transl Res. 2023; 15(5):3579-3585.

PMID: 37303659 PMC: 10250965.

References

Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z . Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012; 18(23):6436-45. DOI: 10.1158/1078-0432.CCR-12-1449. View

Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H . Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008; 68(23):9832-8. DOI: 10.1158/0008-5472.CAN-08-1973. View

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J . A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014; 512(7514):324-7. DOI: 10.1038/nature13387. View

Gattinoni L, Powell Jr D, Rosenberg S, Restifo N . Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006; 6(5):383-93. PMC: 1473162. DOI: 10.1038/nri1842. View

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A . Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13(9):1050-9. DOI: 10.1038/nm1622. View

Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, Biankin A . Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. PMC: 3776390. DOI: 10.1038/nature12477. View

Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y . Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003; 306(1):16-25. DOI: 10.1016/s0006-291x(03)00908-2. View

Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R . Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2):134-44. PMC: 4126516. DOI: 10.1056/NEJMoa1305133. View

Toh J, de Souza P, Lim S, Singh P, Chua W, Ng W . The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Clin Colorectal Cancer. 2016; 15(4):285-291. DOI: 10.1016/j.clcc.2016.07.007. View

10.

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

11.

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

12.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

13.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

14.

Ishiguro T, Sano Y, Komatsu S, Kamata-Sakurai M, Kaneko A, Kinoshita Y . An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. 2017; 9(410). DOI: 10.1126/scitranslmed.aal4291. View

15.

Fritsch E, Hacohen N, Wu C . Personal neoantigen cancer vaccines: The momentum builds. Oncoimmunology. 2014; 3:e29311. PMC: 4121338. DOI: 10.4161/onci.29311. View

16.

Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P . A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med. 1997; 186(5):785-93. PMC: 2199018. DOI: 10.1084/jem.186.5.785. View

17.

Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T . Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol. 2014; 46(1):28-36. PMC: 4238729. DOI: 10.3892/ijo.2014.2737. View

18.

Lu Y, Yao X, Li Y, El-Gamil M, Dudley M, Yang J . Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol. 2013; 190(12):6034-42. PMC: 3679246. DOI: 10.4049/jimmunol.1202830. View

19.

Zhu A, Gold P, El-Khoueiry A, Abrams T, Morikawa H, Ohishi N . First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013; 19(4):920-8. DOI: 10.1158/1078-0432.CCR-12-2616. View

20.

Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, De Plaen E . A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995; 269(5228):1281-4. DOI: 10.1126/science.7652577. View